425 filed Jul 29, 2026 at 08:16 ET
Standard BioTools (LAB) filed an 8-K/A on July 29, 2026, attaching the full Share and Asset Purchase Agreement for the sale of its mass cytometry business to Multiplex Bio Inc., as previously announced on July 28, 2026. The deal includes a $5M base purchase price (paid via promissory note) plus up to $5M in contingent additional consideration tied to a future Qualifying Exit by Multiplex Bio. The transaction is a procedural step in LAB's broader restructuring ahead of its transformative reverse merger with Treeline Biosciences, and its closing is conditioned on the Treeline merger closing substantially concurrently.